Presymptom: development of a novel machine-learning-derived diagnostic test to rule out infection to enable enhanced clinical care and better targeted anti-microbial use

症状前：开发一种新型的机器学习诊断测试来排除感染，从而加强临床护理和更有针对性的抗菌药物使用

• 批准号: 10089281
• 金额: $ 62.02万
• 依托单位: PRESYMPTOM HEALTH LIMITED
• 依托单位国家: 英国
• 项目类别: Investment Accelerator
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10089281
• 关键词: Presymptom; development; novel; machine; learning

Presymptom Health, a UK-based start-up, is pioneering a portfolio of novel, universal, low-cost diagnostic tests and associated interpretive software algorithms to rule out the presence of infection/sepsis in symptomatic patients.Presymptom has developed a prototype version of a simple blood test and associated prototype interpretive software to rule out infection from whole blood in post-operative inflamed SIRS (Systemic Inflammatory Response Syndrome) patients. Results can be used to delay or eliminate the use of antibiotics in such SIRS patients who present with symptoms suggestive of potential infection but who in reality have no infection, allowing such patients to be managed instead on a more appropriate care pathway. This will in turn reduce the spread of Antimicrobial Resistance (AMR) and lead to better patient outcomes.Presymptom's product will comprise a simple blood test to assess host gene expression and associated interpretive software to gauge risk of infection in SIRS patients. The test will run on ubiquitous clinical instrumentation, specifically platforms commonly used within clinical testing labs for routine quantitative RT-PCR based diagnostics, including the many new such instruments deployed since the COVID pandemic. Presymptom's technology platform was discovered based on application of machine learning to a unique fully-annotated presymptomatic database owned by the UK Defence Science & Technologies Laboratory (Dstl).Current diagnostic approaches to assess infection status include:* **Observations**: Temperature/Resp. rate/heart-rate/urine output/blood pressure/O2 saturation/appearance/rash. In general, these lack specificty and lead to overuse of antimicrobials.* **Blood markers**: also lack specificity, CRP, PCT, lactate, urea & electrolytes, glucose, creatine, blood gas, full blood count* **Microbiology&Culture**: blood culture (BC) sets (1-3 days to result, low sensitivity & high false positive), swabs from multiple sites, PCR from swabs if appropriate.The main objective of this project is to develop and validate a rapid novel diagnostic test to rule out the presence of infection in post-operative patients, thereby mitigating AMR, reducing hospital costs and delivering improved patient outcomes.

Presymptom Health是一家总部位于英国的初创公司，正在开拓一种新颖、通用、低成本的诊断测试和相关的解释软件算法，以排除有症状的患者中感染/败血症的存在。Presymptom开发了简单血液测试的原型版本和相关的原型解释软件，以排除术后炎症SIRS中全血的感染（全身炎症反应综合征）患者。结果可用于延迟或消除这些SIRS患者中抗生素的使用，这些患者出现提示潜在感染的症状，但实际上没有感染，从而允许这些患者在更适当的护理途径上进行管理。这将反过来减少抗生素耐药性（AMR）的传播，并导致更好的患者预后。Presymptom的产品将包括一个简单的血液测试，以评估宿主基因表达和相关的解释软件，以衡量SIRS患者的感染风险。该测试将在无处不在的临床仪器上运行，特别是临床检测实验室内常用的常规定量RT-PCR诊断平台，包括自COVID大流行以来部署的许多新仪器。Presymptom的技术平台是基于将机器学习应用于英国国防科学技术实验室（Dstl）拥有的独特的完全注释的presymptom数据库而发现的。目前评估感染状态的诊断方法包括：* 观察 **：温度/呼吸。心率/心率/尿量/血压/O2饱和度/外观/皮疹。一般来说，这些缺乏特异性，并导致过度使用抗菌药物。** 血液指标 **：也缺乏特异性，CRP，PCT，乳酸盐，尿素和电解质，葡萄糖，肌酸，血气，全血细胞计数 * 微生物学和培养 **：血培养（BC）套件（1-3天得出结果，低灵敏度和高假阳性），来自多个部位的拭子，本项目的主要目标是开发和验证一种快速的新型诊断测试，以排除这是一种预防术后患者感染的方法，从而减轻AMR，降低医院成本并改善患者结局。